Current Report Filing (8-k)
04 April 2017 - 10:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 4, 2017
PIERIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Nevada
|
|
001-37471
|
|
EIN
30-0784346
|
(State of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
255 State Street, 9th Floor
Boston, MA 02109
United
States
(Address of principal executive offices, including zip code)
Registrants telephone number, including area code:
857-246-8998
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
On April 4, 2017, Pieris Pharmaceuticals, Inc. presented
IND-enabling
data for
PRS-343,
a
first-in-class
4-1BB/HER2
bispecific, in a poster session at the American
Association for Cancer Research conference (AACR) in Washington, D.C. The poster is furnished as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
Attached hereto as Exhibit 99.2 and incorporated by reference herein is press release regarding the presentation at AACR.
The information set forth under this Item 7.01. Regulation FD Disclosure, including the exhibits attached hereto, shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
|
|
|
99.1
|
|
Industry Conference Presentation of Pieris Pharmaceuticals, Inc., dated April 2017.
|
|
|
99.2
|
|
Press Release dated April 4, 2017.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: April 4, 2017
|
|
|
|
PIERIS PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Lance Thibault
|
|
|
|
|
Name:
|
|
Lance Thibault
|
|
|
|
|
Title:
|
|
Acting Chief Financial Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Industry Conference Presentation of Pieris Pharmaceuticals, Inc., dated April 2017.
|
|
|
99.2
|
|
Press Release dated April 4, 2017.
|
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From Apr 2024 to May 2024
Pieris Pharmaceuticals (NASDAQ:PIRS)
Historical Stock Chart
From May 2023 to May 2024